Jazz Pharmaceuticals (JAZZ) PT Lowered to $175 at Oppenheimer as Erwinaze Deal Terminated

February 12, 2019 12:26 PM

Oppenheimer analyst Esther Rajavelu lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $175.00 (from $180.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

StreetInsider

Log in to your account:

Jazz Pharmaceuticals (JAZZ) PT Lowered to $175 at Oppenheimer as Erwinaze Deal Terminated

Categories

Next Articles